Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | ||
| Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | ||
| Wegovy | semaglutide | Weight management | Do not reimburse | Complete | ||
| Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete | ||
| Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | ||
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
| Vraylar | cariprazine | Bipolar Disorder | Do not reimburse | Complete | ||
| Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
| Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete | ||
| Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete |
Last Updated : May 19, 2024